Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

156 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The role of cytokine DNAs as vaccine adjuvants for optimizing cellular immune responses.
Barouch DH, Letvin NL, Seder RA. Barouch DH, et al. Among authors: seder ra. Immunol Rev. 2004 Dec;202:266-74. doi: 10.1111/j.0105-2896.2004.00200.x. Immunol Rev. 2004. PMID: 15546399 Review.
DNA vaccines: a key for inducing long-term cellular immunity.
Gurunathan S, Wu CY, Freidag BL, Seder RA. Gurunathan S, et al. Among authors: seder ra. Curr Opin Immunol. 2000 Aug;12(4):442-7. doi: 10.1016/s0952-7915(00)00118-7. Curr Opin Immunol. 2000. PMID: 10899026 Review.
CpG oligodeoxynucleotides as vaccine adjuvants in primates.
Verthelyi D, Kenney RT, Seder RA, Gam AA, Friedag B, Klinman DM. Verthelyi D, et al. Among authors: seder ra. J Immunol. 2002 Feb 15;168(4):1659-63. doi: 10.4049/jimmunol.168.4.1659. J Immunol. 2002. PMID: 11823494
Th1 memory: implications for vaccine development.
Foulds KE, Wu CY, Seder RA. Foulds KE, et al. Among authors: seder ra. Immunol Rev. 2006 Jun;211:58-66. doi: 10.1111/j.0105-2896.2006.00400.x. Immunol Rev. 2006. PMID: 16824117 Review.
T-cell quality in memory and protection: implications for vaccine design.
Seder RA, Darrah PA, Roederer M. Seder RA, et al. Nat Rev Immunol. 2008 Apr;8(4):247-58. doi: 10.1038/nri2274. Epub 2008 Mar 7. Nat Rev Immunol. 2008. PMID: 18323851 Review.
TLR9 agonist, but not TLR7/8, functions as an adjuvant to diminish FI-RSV vaccine-enhanced disease, while either agonist used as therapy during primary RSV infection increases disease severity.
Johnson TR, Rao S, Seder RA, Chen M, Graham BS. Johnson TR, et al. Among authors: seder ra. Vaccine. 2009 May 18;27(23):3045-52. doi: 10.1016/j.vaccine.2009.03.026. Epub 2009 Apr 3. Vaccine. 2009. PMID: 19428918 Free PMC article.
Vaccine adjuvants: putting innate immunity to work.
Coffman RL, Sher A, Seder RA. Coffman RL, et al. Among authors: seder ra. Immunity. 2010 Oct 29;33(4):492-503. doi: 10.1016/j.immuni.2010.10.002. Immunity. 2010. PMID: 21029960 Free PMC article. Review.
Immunological and virological mechanisms of vaccine-mediated protection against SIV and HIV.
Roederer M, Keele BF, Schmidt SD, Mason RD, Welles HC, Fischer W, Labranche C, Foulds KE, Louder MK, Yang ZY, Todd JP, Buzby AP, Mach LV, Shen L, Seaton KE, Ward BM, Bailer RT, Gottardo R, Gu W, Ferrari G, Alam SM, Denny TN, Montefiori DC, Tomaras GD, Korber BT, Nason MC, Seder RA, Koup RA, Letvin NL, Rao SS, Nabel GJ, Mascola JR. Roederer M, et al. Among authors: seder ra. Nature. 2014 Jan 23;505(7484):502-8. doi: 10.1038/nature12893. Epub 2013 Dec 18. Nature. 2014. PMID: 24352234 Free PMC article.
CD40 ligand/trimer DNA enhances both humoral and cellular immune responses and induces protective immunity to infectious and tumor challenge.
Gurunathan S, Irvine KR, Wu CY, Cohen JI, Thomas E, Prussin C, Restifo NP, Seder RA. Gurunathan S, et al. Among authors: seder ra. J Immunol. 1998 Nov 1;161(9):4563-71. J Immunol. 1998. PMID: 9794383 Free PMC article.
Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection.
Gurunathan S, Prussin C, Sacks DL, Seder RA. Gurunathan S, et al. Among authors: seder ra. Nat Med. 1998 Dec;4(12):1409-15. doi: 10.1038/4000. Nat Med. 1998. PMID: 9846579
156 results
Jump to page
Feedback